Navigation Links
MannKind Reports Successful Completion of Device Bioequivalence Trial
Date:1/13/2009

VALENCIA, Calif., Jan. 13 /PRNewswire-FirstCall/ -- MannKind Corporation (Nasdaq: MNKD) today announced successful completion of its trial to demonstrate equivalence of its commercial inhaler to the version of the device that was used in clinical trials to deliver AFRESA(TM), MannKind's ultra rapid acting insulin that recently completed Phase 3 clinical trials.

Study 138 - Bioequivalence of Clinical and Commercial Scale Inhalers

Study 138 compared the bioequivalence of MannKind's inhalation device, which underwent some design changes after the initiation of Phase 3 clinical trials in order to make the device more rugged and less costly to manufacture. Clinical trial subjects were administered AFRESA Inhalation Powder from the same bulk lot, according to a randomized two-way crossover protocol, consistent with the standard requirements of bioequivalence testing. As previously announced, this study was requested by FDA at AFRESA's pre-NDA meeting held in July 2008.

Dr. Peter Richardson, MannKind's Chief Scientific Officer, commented, "We were confident from bench testing that the improvements we made with the device had preserved all critical air-flow parameters, but we recognized at our pre-NDA meeting the FDA's desire to validate this fact with in-vivo data. We collaborated with the agency in the design of the study and now have an extensive body of in vitro and in vivo evidence to demonstrate equivalence of the two device versions against a range of measures. Together with the recent announcement that we met the primary end-points of our pivotal Phase 3 program, we now have a clear path to submission of the AFRESA NDA. With study 138 complete, there are no longer any outstanding elements of the NDA and we expect to have the complete NDA submitted to FDA within the next few weeks."'/>"/>

SOURCE MannKind Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. MannKind Corporation to Review Positive Results From Final Two Pivotal Phase 3 Clinical Studies in Type 1 and Type 2 Diabetes
2. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
3. MannKind Addresses Pfizers Announcement Regarding Exubera
4. AcelRx Pharmaceuticals Reports Positive Results from a Clinical Trial of Sublingual Sufentanil/Triazolam NanoTab(TM) Combination (ARX-03) in Treating Procedural Pain and Anxiety
5. Human Genome Sciences Reports Substantial Progress Toward Commercialization and Announces 2009 Goals at JPMorgan Healthcare Conference
6. Pharmasset Reports Fiscal Year End 2008 Financial Results
7. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
8. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
9. Rib-X Pharmaceuticals Reports Positive Top-Line Results from Phase 2 Study of Delafloxacin
10. GSK Reports PROMACTA(R) (eltrombopag) Significantly Increased Platelet Counts and Reduced Bleeding in Long-Term Study of Patients With Chronic ITP
11. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: AST), ... of regenerative medicine, today announced that the third ... -based Rush University Medical Center in a ... doses of AST-OPC1 (oligodendrocyte progenitor cells) in newly ... spinal cord injury (SCI). This represents the final ...
(Date:8/31/2015)... N.J. and STAMFORD, Conn. ... pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue Pharma ... worldwide collaboration agreement for the development and commercialization of ... orexin receptor antagonist entering Phase III clinical development for ... terms of the agreement, Eisai and Purdue Pharma will ...
(Date:8/31/2015)... , Aug. 31, 2015 Bionomics Limited ... and development of innovative therapeutics for the treatment of ... today announced that its BNC101 IND submission has passed ... Bionomics plans to initiate a Phase 1 clinical trial ... with metastatic pancreatic cancer prior to 31 December 2015. ...
Breaking Medicine Technology:Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 4Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 5Asterias Biotherapeutics Concludes Recruitment of Initial Safety Cohort of the SCiStar Phase 1/2a Dose-Escalation Clinical Trial of AST-OPC1 for Complete Cervical Spinal Cord Injury 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 2Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 3Successful BNC101 IND Submission Paves Way for Development of Promising Cancer Stem Cell Drug Candidate 4
... multiple sclerosis, remained relapse-free after three years of treatment ... active brain lesions - the ... - MS, a devastating disease causing progressive disability, affects 2.5 ... including many young adults - FTY720 regulatory filings planned before ...
... basis of methotrexate,resistance and differences in methotrexate response, ... analysis,of the genetic determinants of resistance to the ... could offer a,pathway to predicting such resistance and ... Children,s Research Hospital study., Besides its use ...
Cached Medicine Technology:FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 2FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 3FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 4FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 5FTY720, a novel oral therapy in development for MS, shows sustained benefits for the majority of patients after three years of treatment 6St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 2St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 3St. Jude Gene Study Reveals Basis of Anti-Cancer Drug Resistance in Childhood Leukemia 4
(Date:8/31/2015)... West Orange, NJ (PRWEB) , ... September 01, ... ... in the spine to eliminate chronic back pain – once required a long, ... with a shorter hospital stay, less pain, less blood loss and minimal muscle ...
(Date:8/31/2015)... ... 31, 2015 , ... Dental clinicians from Newcastle University, United ... to learn more about its integrated approach to diabetes care. , Philip Preshaw, ... Cellular Medicine at Newcastle University, and Susan Bissett, National Institute for Health Research ...
(Date:8/31/2015)... CA (PRWEB) , ... August 31, 2015 , ... ... center management, recently opened registration for the company’s second Introduction to Hyperbaric Medicine ... held October 15-18, 2015 aboard the Queen Mary Hotel in Long Beach, CA. ...
(Date:8/31/2015)... Ohio (PRWEB) , ... August 31, 2015 , ... ... Michael as Vice President, Marketing and Corporate Communications. In this capacity, Michael will ... , CareSource is an industry leader in consumer-focused programs that have contributed to ...
(Date:8/31/2015)... , ... August 31, 2015 , ... In an ... the Plastic and Reconstructive Surgery Global Open Journal that discusses the future of 3-D ... discussed how, in the future, customized implants, prosthetics, and other 3-D printed tools could ...
Breaking Medicine News(10 mins):Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 2Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 3Health News:Minimally Invasive Spinal Fusions Squash Back Pain without Arduous Recovery 4Health News:Western Diabetes Institute Collaborates with UK team 2Health News:Western Diabetes Institute Collaborates with UK team 3Health News:Western Diabetes Institute Collaborates with UK team 4Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 2Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 3Health News:Registration Opens for Wound Care Advantage’s Second UHMS Approved 40-Hour Introduction to Hyperbaric Medicine Course 4Health News:CareSource Names Vice President, Marketing and Corporate Communications 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 2Health News:Recent Article on 3-D Printing Highlights the Future of Custom Medical Solutions Using the Technology, says Beverly Hills Physicians 3
... emerging public health threats, early diagnosis of infectious diseases ... the globe where conventional medical tools like microscopes and ... helping to make disease screening quicker and simpler. ... blood or fluid samples are placed. Specific changes in ...
... Sindab Triple Negative Breast Cancer Symposium, sponsored by ... an intimate learning environment in which the most ... be explored. Nationally recognized speakers will review research, ... in TNBC. TNBC affects young women and African ...
... April 26, 2012 - The mitotic spindle, an apparatus ... complex than the standard textbook picture suggests, according to ... Sciences (SEAS). The findings, which result from quantitative ... the journal Cell . The researchers used ...
... Reporter , THURSDAY, April 26 (HealthDay News) -- From the ... was different. She could name 200 dinosaurs by age 3, ... Abby also had difficulty making friends. And teachers ... desk while the other kids sat in a circle reading ...
... guidelines from the American Cancer Society say for many ... and eating a healthy diet can reduce the chance ... after a diagnosis. The recommendations are included in newly ... published early online in CA: A Cancer Journal ...
... communication skills can improve the quality of primary care ... Medical Center researchers report in a study published online ... As ways to improve primary care, the researchers ... and providing time to physicians for personal growth. ...
Cached Medicine News:Health News:UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity 2Health News:UCLA researchers combat global disease with a cell phone, Google Maps and a lot of ingenuity 3Health News:Slicing mitotic spindle with lasers, nanosurgeons unravel old pole-to-pole theory 2Health News:Battling the Bullying of an Autistic Child 2Health News:Battling the Bullying of an Autistic Child 3Health News:Battling the Bullying of an Autistic Child 4Health News:Guidelines say diet, exercise, weight control improve odds after cancer diagnosis 2Health News:Guidelines say diet, exercise, weight control improve odds after cancer diagnosis 3Health News:Physician's mindfulness skills can improve care for patient and provider 2
The Atria 6100 delivers the highest level of clinical performance while incorporating cutting-edge technology to streamline clinic workflow. It offers timely, high-quality, and accurate ECG results c...
The CSV-1000ETDRS10% test face presents the standard ETDRS test at a contrast level of 10%. This test is widely used in clinical studies for the evaluation of refractive surgery and contact lenses....
The CSV-1000SLanC test face provides the same tests as the standard CSV-1000S, except that the acuity test is presented in Landolt C format. , ,This test is very useful when testing patients who cann...
... CSV-1000E contrast sensitivity chart test face is the ... world. This test provides for four (4) rows ... of 8 ft (2.5 meters), these gratings test ... 18 cycles/degree. The CSV-1000E provides a full contrast ...
Medicine Products: